# Morpheus Global Registry

## Study Highlights

- Principal Investigator: Dr. Pierfrancesco Agostoni
- The objective of the study is to evaluate safety and performance of the BioMime™ Morph sirolimus-eluting coronary stent (SES) system in very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm
- The Morpheus Global registry demonstrated favorable safety and performance of BioMime™ Morph SES system in real-world patients with very long coronary lesions



## ❖ Study Design

- **A prospective, multi-centre, single-arm, observational, real-world registry**



A total of 500 subjects to be enrolled from The Netherlands, UK, Italy, Finland, Hungary, Bulgaria, Slovakia, Saudi Arabia, Jordan, South Africa, Indonesia and Malaysia

Follow-up at 1 month, 6 months, 12 months, 24 months and 36 months post-procedure

## ❖ Study Results




**Figure 1: Clinical events**




**Figure 2: Cardiac status**




**Figure 3: Lesion location**




**Figure 4: Lesion classification**




**Figure 5: Stent length**

## ❖ Reference

1. Clinical Trial Registration: NCT02901353 https://clinicaltrials.gov/ct2/show/NCT02901353?term=NCT02901353&draw=2&rank=1.
2. Agostoni P, A multicenter prospective registry of a novel tapered sirolimus-eluting stent for long coronary lesions, EuroPCR 2019